Temozolomide as Maintenance Therapy in Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
Temozolomide, a nonclassic oral alkylating agent, may delay progression in sequence with
chemotherapy. This phase II trial was designed to evaluate the role of Temozolomide following
4 or 6 cycles of first-line treatment in patients with newly diagnosed SCLC.